A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. by Arnaud, Lionel et al.
A dominant mutation in the gene encoding the
erythroid transcription factor KLF1 causes a congenital
dyserythropoietic anemia.
Lionel Arnaud, Carole Saison, Virginie Helias, Nicole Lucien, Dominique
Steschenko, Marie-Catherine Giarratana, Claude Prehu, Bernard Foliguet,
Lory Montout, Alexandre De Brevern, et al.
To cite this version:
Lionel Arnaud, Carole Saison, Virginie Helias, Nicole Lucien, Dominique Steschenko, et al..
A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a
congenital dyserythropoietic anemia.. American Journal of Human Genetics, Elsevier (Cell
Press), 2010, 87 (5), pp.721-7. <10.1016/j.ajhg.2010.10.010>. <inserm-00550723>
HAL Id: inserm-00550723
http://www.hal.inserm.fr/inserm-00550723
Submitted on 29 Dec 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Arnaud et al. 
 1
A dominant mutation in the gene encoding the erythroid transcription factor 
KLF1 causes a congenital dyserythropoietic anemia 
 
Lionel Arnaud,1,* Carole Saison,1 Virginie Helias,1 Nicole Lucien,1 Dominique Steschenko,2 
Marie-Catherine Giarratana,3 Claude Prehu,4 Bernard Foliguet,5 Lory Montout,1,6,7 Alexandre G. 
de Brevern,1,6,7 Alain Francina,8 Pierre Ripoche,1,7 Odile Fenneteau,9 Lydie Da Costa,9,10,19 
Thierry Peyrard,1,11 Gail Coghlan,12 Niels Illum,13 Henrik Birgens,14 Hannah Tamary,15 Achille 
Iolascon,16,17 Jean Delaunay,18 Gil Tchernia,10,20 and Jean-Pierre Cartron1 
 
1Institut National de la Transfusion Sanguine, 75015 Paris, France ; 
2Hôpital d’Enfants de Brabois, CHU de Nancy, 54511 Vandoeuvre-les-Nancy, France ; 
3UMR_S 938, INSERM, Faculté de Médecine Pierre et Marie Curie, Université Pierre et Marie 
Curie - Paris 6, 75012 Paris, France ; 
4Laboratoire de Biochimie et Génétique, CHU Hôpital Henri Mondor, 94010 Créteil, France ; 
5Service commun de microscopie électronique, Faculté de Médecine, Université de Nancy, 54506 
Vandoeuvre-les-Nancy, France ; 
6Dynamique des Structures et Interactions des Macromolécules Biologiques, DSIMB, 75015 
Paris, France ; 
7UMR_S 665, INSERM, Institut National de la Transfusion Sanguine, Université Paris Diderot - 
Paris 7, 75015 Paris, France ; 
8Hospices civils de Lyon, Hôpital Edouard Herriot, Unité de Pathologie Moléculaire du Globule 
Rouge, 69003 Lyon, France ; 
9Laboratoire d’Hématologie Biologique, CHU Hôpital Robert Debré, 75019 Paris, France ; 
Arnaud et al. 
 2
10Laboratoire d’Hématologie, Hôpital de Bicêtre, 94275 Le Kremlin Bicêtre, France ; 
11Centre National de Référence pour les Groupes Sanguins, CNRGS, 75011 Paris, France ; 
12Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB  R3A 1S1 
Canada ; 
13Hans Christian Andersen Children’s Hospital, Odense University Hospital, 5000 Odense, 
Denmark ; 
14Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark ; 
15Pediatric Hematology Unit, Schneider Children's Medical Center of Israel, 49202 Petach 
Tikvah, Israel ; 
16Department of Biochemistry and Medical Biotechnologies, University Federico II of Naples, 
80131 Naples, Italy ; 
17CEINGE - Biotecnologie Avanzate, 80145 Naples, Italy ; 
18UMR_S 779, INSERM, Faculté de Médecine Paris-Sud, Université Paris-Sud, 94275 Le 
Kremlin-Bicêtre, France ; 
19Present address : UMR 1009, INSERM, Institut de Cancérologie Gustave Roussy, Université 
Paris-Sud -  Paris 11, 94805 Villejuif, France ; 
20Present address : Ministère de la Santé, 75007 Paris, France ; 
 
*Correspondence : larnaud@ints.fr 
Arnaud et al. 
 3
Summary  
The congenital dyserythropoietic anemias (CDAs) are inherited red blood cell disorders, 
whose hallmarks are ineffective erythropoiesis, hemolysis and morphological abnormalities of 
erythroblasts in bone marrow. We have identified a missense mutation in KLF1 of patients with a 
hitherto unclassified CDA.  KLF1 is an erythroid transcription factor and extensive studies in 
mouse models have shown it to play a critical role in the expression of globin genes, but also a 
wide spectrum of genes potentially essential for erythropoiesis. The unique features of this CDA 
confirm the key role of KLF1 during human erythroid differentiation. Furthermore, we show that 
the mutation has a dominant negative effect on KLF1 transcriptional activity and unexpectedly 
abolishes the expression of the water channel AQP1 and the adhesion molecule CD44. Thus, the 
study of this disease-causing mutation in KLF1 provides further insights on the roles of this 
transcription factor during erythropoiesis in human. 
 
Main text 
The CDAs represent a heterogeneous group of rare congenital anemias predominantly caused 
by dyserythropoiesis in the bone marrow.1 Three major (types I to III) and several minor 
subgroups have been differentiated, mainly according to the morphological abnormalities of 
erythroblast nuclei observed in bone marrow smears (e.g. chromatin bridges or double nuclei).2,3 
The gene responsible for CDA I (MIM 224120) was identified by positional cloning in 20024 and 
coined CDAN1 (MIM 607465) but its function remains to be elucidated. The gene responsible for 
CDA II (MIM 224100) has recently been shown to encode SEC23B (MIM 610512), a subunit of 
the COPII coat protein complex involved in the vesicular transport between the endoplasmic 
reticulum and Golgi apparatus, whose erythroid-specific role was unsuspected.5,6 Although CDA 
I and CDA II represent most cases, the identification of causative genetic defects in other CDA 
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subgroups or in patients with unclassified CDA may offer further insights into the different 
pathways underlying erythropoiesis. 
The first CDA patient investigated in this study (male patient ME) was born at 28 weeks’ 
gestation to non-consanguineous healthy parents, in a context of acute fetal distress. Hydrops 
fetalis-associated anemia had been detected at 23 weeks’ gestation and treated with two 
intrauterine transfusions; the karyotype of the fetus was normal. The neonatal examination 
revealed severe hyperbilirubinemia, hepatomegaly, hypertrophic cardiomyopathy as well as 
several dysmorphic features (micropenis, hypospadia, large anterior fontanel, hypertelorism). 
Anemia did not improve after birth and required transfusions. At 4 months of age, the analysis of 
bone marrow smears showed marked hyperplasia of the erythroid lineage, diagnosing CDA, but 
the dysplastic changes in the erythroblasts did not clearly fit any classification of CDA (Figure 
S1). Despite treatments with erythropoietin or interferon-alpha, the hemolytic anemia persisted 
and required recurrent transfusions (2-3 week interval) until a splenectomy was performed at 4 
years of age (splenomegaly with no pathologic features). Shortly thereafter, transfusion 
independence was achieved with hemoglobin levels stabilized at around 8.0 g/dL (Table S1). At 
13 years of age, patient ME showed short stature (height -3SD, weight -2SD) despite growth 
hormone therapy and treatment for hypothyroidism, and thalassemic facies. 
A striking feature of patient ME’s CDA was the very large number of nucleated red blood 
cells in his peripheral blood, i.e. 210% of white blood cells before splenectomy and up to 1,000% 
thereafter (Figure 1A and Table S1). Most of these circulating nucleated red blood cells were 
orthochromatic erythroblasts but only a few of them were enucleating, which suggested a failure 
of terminal erythroid differentiation. Their analysis by electron microscopy revealed various 
ultrastructural abnormalities, especially atypical cytoplasmic inclusions and enlarged nuclear 
pores (Figure S2). The in vitro study of erythroid differentiation of CD34+ cells7 isolated from 
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patient ME’s peripheral blood showed normal proliferation and differentiation but impaired 
enucleation capacity (Figure 1B). Furthermore, when we analyzed by flow cytometry a panel of 
markers on the surface of his erythrocytes (Figure S3) we noticed the absence of CD44, which 
was confirmed by western blot analysis (Figure 1C), as well as reduced expression of two other 
adhesion molecules, BCAM and ICAM4. CD44 was similarly absent from his mature 
erythrocytes and circulating erythroblasts, but present on his granulocytes and all the other 
leukocyte populations (Figure 1D and Figure S4) suggesting that only the erythroid lineage was 
affected, consistent with a CDA trait. We also found that patient ME’s erythrocytes were 
deficient in the water channel AQP1 (Figure 1C) and consequently, had a reduced water 
permeability as those of the very rare AQP1-/- individuals8 (Figure S5). Patient ME’s CDA was 
altogether unique and certainly different from CDA I and CDA II, as suggested by bone marrow 
analysis, which was later confirmed by the absence of mutations in CDAN1 and SEC23B (data 
not shown). 
In order to identify the causative genetic defect, fresh blood samples were taken from patient 
ME and his relatives after obtaining a signed informed consent for genetic analysis, and genomic 
DNA was extracted. After exploring without success the possibility of an inherited recessive 
mutation by performing a SNP-based genome-wide screen in patient ME’s family (Affymetrix 
GeneChip Human Mapping 250K Nsp Array, data not shown), we thought that this unique CDA 
might be caused by a de novo mutation in a transcription factor essential for expression of CD44 
(MIM 107269) and AQP1 (MIM 107776) amongst others. Since CD44 deficiency was apparently 
restricted to the erythroid lineage, we first focused our analysis on erythroid transcription factors 
such as GATA1 or KLF1 (also known as EKLF).9,10 GATA1 represented an attractive 
candidate11,12 but no mutations in GATA1 (MIM 305371) were detected (data not shown). 
Sequencing of KLF1 (MIM 600599) (Table S2) in patient ME revealed the presence of two 
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heterozygous mutations: a T to C transition in exon 2 (NM_006563.3:c.304T>C, 
NP_006554.1:p.Ser102Pro) and a G to A transition in exon 3 (NM_006563.3:c.973G>A, 
NP_006554.1:p.Glu325Lys) (Figure S6). A comparison with the NCBI dbSNP database (Build 
131) showed that c.304T>C mutation corresponded to a previously reported SNP (rs2072597) 
and was unlikely pathogenic; this was consistent with rs2072597 heterozygosity of his healthy 
mother (data not shown). In contrast, c.973G>A mutation had never been reported and was not 
present in 96 regular blood donors nor in patient ME’s relatives (Figure 2A and data not shown) 
suggesting it was the disease-causing mutation. 
To confirm that KLF1 mutation c.973G>A was responsible for this unique CDA, we 
searched for it in other patients. Female patient SF was extensively studied in the 90s and her 
atypical CDA showed striking similarities with patient’s ME: combined deficiency of CD44 and 
AQP1 on erythrocytes,13 circulating erythroblasts,14 unique ultrastructural abnormalities in 
erythroblasts,15 as well as increased electrophoretic mobility of the erythrocyte membrane protein 
Band 313 (Figure S7). When we sequenced KLF1 in patient SF, we found the same heterozygous 
KLF1 mutation c.973G>A as in patient SF (Figure 2A), corroborating that this mutation was 
responsible for this type of CDA. Of note, analysis of KLF1 haplotypes of patients ME 
(c.[304T>C; 973G>A]+[=]) and SF (c.[973G>A]+[=]) does not support the hypothesis of a 
founder effect for the pathogenic KLF1 mutation c.973G>A, which is consistent with a de novo 
mutation. In addition to the previously mentioned unique features of this CDA, patient SF was 
shown to express embryonic ζ-globin chain in the majority of her erythrocytes, along with high 
levels of fetal hemoglobin.14 When we analyzed patient ME’s hemoglobin by isoelectric focusing 
(Figure 1E), we similarly found large amounts of fetal hemoglobin as well as an unusual 
hemoglobin, migrating like embryonic hemoglobin Portland (ζ2γ2 tetramer) which was confirmed 
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by reverse phase liquid chromatography (Figure S8). Thus, KLF1 mutation c.973G>A was 
associated with a profound dysregulation of globin gene expression and provided in vivo 
evidence of the critical role KLF1 in this complex transcriptional regulation in human, as 
predicted by thalassemia-associated mutations in the proximal KLF1 binding sites of β-globin 
gene16 and extensive studies in mouse models.17-19 Interestingly, while this manuscript was being 
finalized, Borg et al.20 reported the identification of a defective KLF1 allele in a large Maltese 
family which causes the persistence of high levels of fetal hemoglobin in adults - a benign and 
usually asymptomatic condition known to alleviate the severity of β-thalassemia and sickle cell 
disease - and further demonstrated that KLF1 indirectly downregulates fetal globin gene 
expression by activating BCL11A expression. 
The pathogenic KLF1 mutation c.973G>A results in the substitution of the evolutionary 
conserved glutamate 325 by a lysine (E325K) in the second zinc finger (ZF2) of KLF1 (Figure 
2B). As arginine 322 and arginine 328, glutamate 325 is predicted to contact DNA16 (Figure 2C). 
In order to investigate the possible structural effect of E325K mutation, we built a new structural 
model for the zinc finger domain of KLF1 based on the X-ray structures of Wilms’ tumor protein 
in complex with DNA.21 The currently used models of KLF1 are based on the structure of Zif268 
bound to DNA22 but alignment of their respective zinc-finger domains requires a two amino-acid 
gap in KLF1 ZF2, which significantly changes the local topology. According to the new 
structural model, glutamate 325 is located on a helix and directed toward the DNA backbone 
(Figure 2D, upper left panel). The single amino acid mutation E325K does not alter the overall 
topology of KLF1 zinc finger domain, but mainly affects the side chain of residue 325 (Figure 
2D, lower panels). Actually, this charge reversal mutation enhances the electrostatic interaction 
between KLF1 and the DNA, and potentially creates a novel hydrogen bond (Figure 2D, upper 
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right panel). Thus, E325K mutation is predicted to stabilize, rather than disrupt, the binding of 
KLF1 to its DNA target sequences. 
Before testing the potential effect of E325K mutation on KLF1 transcriptional activity, we 
first wanted to check whether this mutation did not affect the stability or cellular localization of 
the mutant protein. For this purpose, we constructed vectors encoding either wild type (WT) or 
mutant (E325K) KLF1 tagged with a Flag epitope at the N-terminus to allow its detection, and 
transfected them into human erythroid K-562 cells. Flag-tagged KLF1 E325K showed the same 
expression level as the wild type protein by western blot analysis (Figure 3A) and showed the 
same nuclear localization by immunofluorescence analysis (Figure 3B). The combined 
deficiency of CD44 and AQP1 observed in this unique CDA suggested that AQP1 and CD44 
genes were direct targets of KLF1, which was consistent with the presence of several potential 
KLF1 binding sites (CCNCNCCCN)16 upstream of their respective initiating codons. Therefore, 
we studied the effect of E235K mutation on KLF1 transcriptional activity with CD44 and AQP1 
promoter-reporter assays in K-562 cells. Flag-tagged KLF1 WT was able to activate CD44 and 
AQP1 promoters, whereas the mutant E325K showed a markedly reduced transcriptional activity 
(Figures 3C and 3D). Furthermore, when we co-expressed KLF1 E325K with KLF1 WT in 
order to mimic heterozygosity of patients ME and SF, we observed that KLF1 E325K was able to 
inhibit the activation of CD44 promoter induced by KLF1 WT (Figure 3D). On the basis of this 
data, we conclude that E325K mutation has a dominant negative effect on the transcriptional 
activity of KLF1, in total agreement with the phenotype of heterozygous patients. 
This study describes a missense KLF1 mutation responsible for a human pathology, a 
hitherto unclassified CDA. Interestingly, a new CDA patient with KLF1 mutation c.973G>A has 
just been identified (female patient SE; A.I., unpublished data) suggesting that this type of CDA 
may be less rare than expected. The previously reported KLF1 mutations, found in the 
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heterozygous state too, are responsible for the blood group In(Lu) phenotype23 (MIM 111150) 
which is mainly characterized by a reduced expression of Lu (also known as BCAM) on 
erythrocytes, but not associated with any pathology. Of note, patient SF does not show a reduced 
expression of Lu (Figure S9) indicating that KLF1 mutation E325K is not directly responsible 
for the reduced expression of Lu observed in patient ME (Figure S3). We assume that distinct 
KLF1 mutations may differently affect the gene repertoire of this transcription factor, thus 
leading to different phenotypes as observed with GATA1 mutations.11,12 Fortuitously, while this 
manuscript was being finalized, Siateckla et al.24 reported that the mouse mutation Nan, a 
dominant ethylnitrosourea-induced mutation causing hemolytic anemia, corresponds to a 
missense Klf1 mutation (E339D) affecting the expression of only a subset of its target genes, and 
further showed that E339D mutation indeed alters Klf1 DNA binding to only a subset of its target 
sequences. Of note, glutamate 339 in mouse Klf1 is the equivalent of glutamate 325 in human 
KLF1; however, Klf1 mutation E339D is intrinsically different from KLF1 mutation E325K due 
to the opposite charge of the mutant residue (see structure prediction above), which is consistent 
with the distinct resulting pathologies in mouse and human. Extensive studies with mouse models 
suggested that KLF1 played a global role during erythropoiesis by regulating a wide spectrum of 
genes19,25,26  but also organizing nuclear hubs for efficient and coordinated transcription of genes 
co-regulated with β-globin gene.27,28 This study provides in vivo evidence that human KLF1 
plays a critical role in the regulation of fetal globin genes, as recently demonstrated by Borg et 
al.20 (see above), but also other unexpected genes like AQP1 or CD44. While AQP1 deficiency in 
human doesn’t cause dyserythropoiesis,8 we can not exclude that CD44 deficiency may 
contribute, even though CD44 is dispensable for mouse erythropoiesis.29 Future studies will be 
required to identify the KLF1 target genes whose expression is essential for human erythropoiesis 
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but deficient in this form of CDA. Finally, we propose that KLF1 should be systematically 
sequenced as a novel candidate gene in all CDA cases with unknown genetic cause, which may 
eventually lead to the discovery of other pathogenic KLF1 mutations. 
 
Supplemental Data 
Supplemental Data include nine figures and two tables. 
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Figure Titles and Legends 
 
Figure 1. Analysis of the peripheral blood of CDA patient ME featuring unique 
abnormalities. 
(A) Peripheral blood smear from the patient (right panels, sample taken on 2008/10/28) or a 
control (left panel, sample taken at the same time) stained with May-Grünwald Giemsa, showing 
the large number of circulating erythroblasts (purple nuclei) as well as poikilocytosis, 
anisocytosis and fragmented erythrocytes in the patient; the scale bars represent 40 µm. 
(B) Study of the number of enucleated cells during in vitro erythroid differentiation of CD34+ 
cells from the patient (purple, sample taken on 2005/10/25) or a control donor (blue), showing 
markedly reduced enucleation capacity of the patient’s cell culture. 
(C) Western blot analysis of CD44, CD55, AQP1 and p55 in erythrocyte membrane lysates from 
the patient (sample taken on 2004/06/07) his healthy mother (C2) or a random control (C1), 
showing the combined deficiency of CD44 and AQP1 in the patient’s erythrocytes. 
(D) Flow cytometry analysis of CD44 on mature erythrocytes (left panels) and granulocytes 
(right panels) from the patient (bottom panels, sample taken on 2010/01/05) and a control (top 
panels, sample taken at the same time) showing the erythroid-specific deficiency of CD44 in the 
patient. For the analysis of erythrocytes, whole blood samples were co-stained with 
fluorochrome-conjugated anti-CD44 (black histogram) or isotype control antibody (white 
histogram) and anti-CD71, and the mature erythrocytes were gated on FSS, SCC and CD71- to 
eliminate the reticulocytes and erythroblasts; for the analysis of granulocytes, nucleated blood 
cells were first isolated by hypotonic erythrocyte lysis, co-stained as above but directly gated on 
FSC and SSC. 
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(E) Isoelectric focusing analysis of the different hemoglobin (Hb) variants in the patient (sample 
taken on 2008/10/28) and two controls (C1 and C2) showing atypical globin expression in the 
patient. The patient exhibited very high levels of fetal Hb (α2γ2 tetramer, 37.3%, normal range: 
less that 1%) as well as embryonic Hb Portland (ζ2γ2 tetramer, 2.9%, normal range: absent) as 
ascertained by reverse phase liquid chromatography; adult HbA and HbA2 were at 55.5% (α2β2 
tetramer, normal range: 90-100%) and 1.2% (α2δ2 tetramer, normal range: 2-3%) respectively. 
Extensive sequencing of patient ME’s globin loci detected no gross abnormalities but a 
heterozygous mutation in α1-globin gene (c.62_63insT, p.His21fsX36) which could not be 
responsible for the profound β-globin locus dysregulation and was indeed present in his healthy 
paternal aunt. Of note, patient SF was carrier of a 4bp deletion in the promoter of Aγ-globin gene, 
as her healthy father14. 
All studied blood samples were taken after splenectomy and at least 6 months post transfusion. 
 
Figure 2. Identification of the KLF1 mutation associated with this CDA and structural 
analysis of the mutant transcription factor. 
(A) Detail of KLF1 sequencing in patient ME, his unaffected mother and sister, and unrelated 
patient SF, showing the same heterozygous KLF1 mutation in both CDA patients. The 
experimental sequences were aligned with the NCBI reference sequence of KLF1 
(NG_013087.1). Genomic DNA samples from patient ME’s father and patient SF’s parents were 
not available. 
(B) Diagram showing the structure of KLF1 (based on NG_013087.1) and its products, with the 
localization of the mutation c.973G>A, p.Glu325Lys (E325K) found in both CDA patients. KLF1 
consists of 3 exons (boxes; black color represents coding regions and grey represents untranslated 
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regions) and encodes a peptide of 362 amino acids with a proline-rich domain at the amino-
terminus (transactivation domain in brown) and three C2H2-type zinc fingers (ZF) at the carboxy-
terminus (DNA-binding domain in green). The pathogenic mutation is located in the third exon 
and encodes a single amino acid change in the second zinc finger of the transcription factor. 
(C) Sequence alignment of the second zinc finger of KLF1 from various mammalian species, 
showing the conservation of a glutamate at amino acid position 325 (red box). The two cysteines 
and the two histidines contacting Zn2+ are indicated in bold, and the three conserved residues 
contacting the DNA are indicated by stars. 
(D) Modeling structure of wild type (left) and variant E325K (right) zinc-finger domain of KLF1 
showing the enhanced electrostatic interaction between the variant E325K and the DNA 
backbone. The change of glutamate to lysine at position 325 has a double effect by reversing the 
side-chain charge from negative to positive, and extending the side-chain length toward the 
negatively charged DNA backbone; the putative hydrogen bond created by E325K mutation is 
shown as a yellow dashed line. The bottom panels show the overall structure of the protein-DNA 
complexes, as well as the electrostatic potential surfaces (negative in red, positive in blue) of wild 
type and variant proteins; the top panels show a close-up view of a cartoon representation of the 
region around residue 325, highlighting as sticks the side chain of residue 325 (orange) and the 
closest nucleotide (light blue); of note, residue 325 is not oriented toward the nucleotide base but 
the phosphate.  
 
Figure 3. Characterization of the effect of E325K mutation on KLF1 function. 
(A) Western blot analysis of transfected human erythroid K-562 cells showing that E325K 
mutation does not affect the stability of KLF1. Constructs encoding Flag-tagged KLF1 wild type 
(WT) or mutant (E325K), or empty vector, were transfected in K-562 cells, and protein 
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expression was analyzed after 24h by western blot with an anti-Flag and an anti-GAPDH 
(loading control). 
(B) Immunofluorescence analysis of transfected K-562 cells showing that E325K mutation does 
not affect the nuclear localization of KLF1. K-562 cells transfected as in (a) were analyzed after 
24h by immunofluorescence with an anti-Flag (green) along with propidium iodide for DNA 
staining (red). No anti-Flag staining was detected in K-562 cells transfected with the empty 
vector (data not shown). 
(C) AQP1 promoter-reporter assay in K-562 cells showing that E325K mutation affects the 
transcriptional activity of KLF1. K-562 cells were co-transfected with an AQP1 promoter-
Photinus luciferase (Pluc) construct and a HSV-TK promoter-Renilla luciferase (Rluc) construct 
for normalization, along with 2 µg of the indicated KLF1 constructs, and the luciferase activities 
were analyzed after 24h; the results are shown as means ± s.d. (n=3) of Pluc activity normalized 
by Rluc activity. 
(D) CD44 promoter-reporter assay in K-562 cells showing that E325K mutation has a dominant 
negative effect on the transcription activity of KLF1. Not only has KLF1 E325K a markedly 
reduced transcriptional activity, but also it is able to impede the transcriptional activity of co-
expressed KLF1 WT. K-562 cells were co-transfected with a CD44 promoter-Pluc construct and 
a HSV-TK promoter-Rluc construct for normalization, along with 2 or 1 µg of the KLF1 
constructs as indicated, and the luciferase activities were analyzed after 24h; the results are 
shown as means ± s.d. (n=3) of Pluc activity normalized by Rluc activity. 
 
Arnaud et al. 
 16
References 
 
1 R. Renella, W.G. Wood (2009) The congenital dyserythropoietic anemias. Hematol Oncol Clin 
North Am 23, 283-306 
 
2 H. Heimpel, F. Wendt, D. Klemm, H. Schubothe, L. Heilmeyer (1968) [Congenital 
dyserythropoietic anemia]. Arch Klin Med 215, 174-94 
 
3 H. Heimpel, K. Kellermann, N. Neuschwander, J. Hogel, K. Schwarz (2010) The 
morphological diagnosis of congenital dyserythropoietic anemia: results of a quantitative analysis 
of peripheral blood and bone marrow cells. Haematologica 95, 1034-6 
 
4 O. Dgany, N. Avidan, J. Delaunay, T. Krasnov, L. Shalmon, H. Shalev, T. Eidelitz-Markus, J. 
Kapelushnik, D. Cattan, A. Pariente et al. (2002) Congenital dyserythropoietic anemia type I is 
caused by mutations in codanin-1. Am J Hum Genet 71, 1467-74 
 
5 K. Schwarz, A. Iolascon, F. Verissimo, N.S. Trede, W. Horsley, W. Chen, B.H. Paw, K.P. 
Hopfner, K. Holzmann, R. Russo et al. (2009) Mutations affecting the secretory COPII coat 
component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet 41, 936-40 
 
6 P. Bianchi, E. Fermo, C. Vercellati, C. Boschetti, W. Barcellini, A. Iurlo, A.P. Marcello, P.G. 
Righetti, A. Zanella (2009) Congenital dyserythropoietic anemia type II (CDAII) is caused by 
mutations in the SEC23B gene. Hum Mutat 30, 1292-8 
 
7 M.C. Giarratana, L. Kobari, H. Lapillonne, D. Chalmers, L. Kiger, T. Cynober, M.C. Marden, 
H. Wajcman, L. Douay (2005) Ex vivo generation of fully mature human red blood cells from 
hematopoietic stem cells. Nat Biotechnol 23, 69-74 
 
8 G.M. Preston, B.L. Smith, M.L. Zeidel, J.J. Moulds, P. Agre (1994) Mutations in aquaporin-1 
in phenotypically normal humans without functional CHIP water channels. Science 265, 1585-7 
 
9 S.I. Kim, E.H. Bresnick (2007) Transcriptional control of erythropoiesis: emerging mechanisms 
and principles. Oncogene 26, 6777-94 
 
10 V.G. Sankaran, J. Xu, S.H. Orkin (2010) Advances in the understanding of haemoglobin 
switching. Br J Haematol 149, 181-94 
 
11 L.M. Hollanda, C.S. Lima, A.F. Cunha, D.M. Albuquerque, J. Vassallo, M.C. Ozelo, P.P. 
Joazeiro, S.T. Saad, F.F. Costa (2006) An inherited mutation leading to production of only the 
short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38, 807-12 
 
12 K.E. Nichols, J.D. Crispino, M. Poncz, J.G. White, S.H. Orkin, J.M. Maris, M.J. Weiss (2000) 
Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in 
GATA1. Nat Genet 24, 266-70 
 
Arnaud et al. 
 17
13 S.F. Parsons, J. Jones, D.J. Anstee, P.A. Judson, B. Gardner, E. Wiener, J. Poole, N. Illum, 
S.N. Wickramasinghe (1994) A novel form of congenital dyserythropoietic anemia associated 
with deficiency of erythroid CD44 and a unique blood group phenotype [In(a-b-), Co(a-b-)]. 
Blood 83, 860-8 
 
14 W. Tang, S.P. Cai, B. Eng, M.C. Poon, J.S. Waye, N. Illum, D.H. Chui (1993) Expression of 
embryonic zeta-globin and epsilon-globin chains in a 10-year-old girl with congenital anemia. 
Blood 81, 1636-40 
 
15 S.N. Wickramasinghe, N. Illum, P.D. Wimberley (1991) Congenital dyserythropoietic 
anaemia with novel intra-erythroblastic and intra-erythrocytic inclusions. Br J Haematol 79, 322-
30 
 
16 W.C. Feng, C.M. Southwood, J.J. Bieker (1994) Analyses of beta-thalassemia mutant DNA 
interactions with erythroid Kruppel-like factor (EKLF), an erythroid cell-specific transcription 
factor. J Biol Chem 269, 1493-500 
 
17 B. Nuez, D. Michalovich, A. Bygrave, R. Ploemacher, F. Grosveld (1995) Defective 
haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature 375, 316-8 
 
18 A.C. Perkins, A.H. Sharpe, S.H. Orkin (1995) Lethal beta-thalassaemia in mice lacking the 
erythroid CACCC-transcription factor EKLF. Nature 375, 318-22 
 
19 R. Drissen, M. von Lindern, A. Kolbus, S. Driegen, P. Steinlein, H. Beug, F. Grosveld, S. 
Philipsen (2005) The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism 
and membrane stability. Mol Cell Biol 25, 5205-14 
 
20 J. Borg, P. Papadopoulos, M. Georgitsi, L. Gutierrez, G. Grech, P. Fanis, M. Phylactides, A.J. 
Verkerk, P.J. van der Spek, C.A. Scerri et al. (2010) Haploinsufficiency for the erythroid 
transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 42, 801-5 
 
21 R. Stoll, B.M. Lee, E.W. Debler, J.H. Laity, I.A. Wilson, H.J. Dyson, P.E. Wright (2007) 
Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol 
372, 1227-45 
 
22 M. Elrod-Erickson, T.E. Benson, C.O. Pabo (1998) High-resolution structures of variant 
Zif268-DNA complexes: implications for understanding zinc finger-DNA recognition. Structure 
6, 451-64 
 
23 B.K. Singleton, N.M. Burton, C. Green, R.L. Brady, D.J. Anstee (2008) Mutations in 
EKLF/KLF1 form the molecular basis of the rare blood group In(Lu) phenotype. Blood 112, 
2081-8 
 
24 M. Siatecka, K.E. Sahr, S.G. Andersen, M. Mezei, J.J. Bieker, L.L. Peters (2010) Severe 
anemia in the Nan mutant mouse caused by sequence-selective disruption of erythroid Kruppel-
like factor. Proc Natl Acad Sci U S A 107, 15151-6 
 
Arnaud et al. 
 18
25 D. Hodge, E. Coghill, J. Keys, T. Maguire, B. Hartmann, A. McDowall, M. Weiss, S. 
Grimmond, A. Perkins (2006) A global role for EKLF in definitive and primitive erythropoiesis. 
Blood 107, 3359-70 
 
26 M.R. Tallack, T. Whitington, W.S. Yuen, E.N. Wainwright, J.R. Keys, B.B. Gardiner, E. 
Nourbakhsh, N. Cloonan, S.M. Grimmond, T.L. Bailey et al. (2010) A global role for KLF1 in 
erythropoiesis revealed by ChIP-seq in primary erythroid cells. Genome Res 20, 1052-63 
 
27 G.P. Patrinos, M. de Krom, E. de Boer, A. Langeveld, A.M. Imam, J. Strouboulis, W. de Laat, 
F.G. Grosveld (2004) Multiple interactions between regulatory regions are required to stabilize 
an active chromatin hub. Genes Dev 18, 1495-509 
 
28 S. Schoenfelder, T. Sexton, L. Chakalova, N.F. Cope, A. Horton, S. Andrews, S. Kurukuti, 
J.A. Mitchell, D. Umlauf, D.S. Dimitrova et al. (2010) Preferential associations between co-
regulated genes reveal a transcriptional interactome in erythroid cells. Nat Genet 42, 53-61 
 
29 R. Schmits, J. Filmus, N. Gerwin, G. Senaldi, F. Kiefer, T. Kundig, A. Wakeham, A. 
Shahinian, C. Catzavelos, J. Rak et al. (1997) CD44 regulates hematopoietic progenitor 
distribution, granuloma formation, and tumorigenicity. Blood 90, 2217-33 
 
 
 
Control CDA patient
C1 CDA C2
fetal (F)
adult (A)
embryonic
Hb+
-
adult (A2)
150
100
75
50
37
25
kDa C1
CD44
CDA C2
CD55
C1 CDA C2
AQP1
C1 CDA C2
p55
C1 CDA C2
Control
CDA
patient
Erythrocytes Granulocytes
ev
en
ts
ev
en
ts
CD44
B C
D E
0
20
40
60
80
7 9 11 13 15 17 19 21
Days in culture
P
er
ce
nt
ag
e
of
 e
nu
cl
ea
te
d
ce
lls Control
CDA patient
P
er
ce
nt
ag
e
of
 e
nu
cl
ea
te
d
ce
lls
A
Arnaud et al., Figure 1
proline-rich domain ZF3ZF1 ZF2
1 362
KLF1
c.973G>A
p.Glu325Lys
(E325K)
KLF1
19p13
ex1 ex2 ex3
human GEKPYACTWEGCGWRFARSDELTRHYRKHTG
macaque  GEKPYACTWEGCGWRFARSDELTRHYRKHTG
cow GEKPYACTWDGCGWRFARSDELTRHYRKHTG
pig GEKPYACTWDGCGWRFARSDELTRHYRKHTG
dog  GEKPYACTWDGCGWRFARSDELTRHYRKHTG
rabbit GEKPYACTWDGCGWKFARSDELTRHYRKHTG
mouse  GEKPYACSWDGCDWRFARSDELTRHYRKHTG
rat  GEKPYACSWDGCNWRFARSDELTRHYRKHTG
*  *  *
A B
D
KLF1 ZF2
C
K325E325
CDA patient ME
KLF1
CDA patient SF
Patient ME’s
mother
Patient ME’s
sister
G
A
G
A
325
Arnaud et al., Figure 2
A B
C D
kDa
66
55
37
31
GAPDH
Flag-KLF1
1 32
+
-
-
-
+
-
-
-
+
empty vector
KLF1 WT
KLF1 E325K
0
50
100
150
200
2 - -
- 2 -
- - 2
empty vector
KLF1 WT
KLF1 E325K
R
el
at
iv
e 
in
du
ct
io
n 
of
 A
Q
P
1 
pr
om
ot
er
R
el
at
iv
e 
in
du
ct
io
n 
of
 A
Q
P
1 
pr
om
ot
er
2 - -
- 2 -
- - 2
empty vector
KLF1 WT
KLF1 E325K
0
10
20
30
40
R
el
at
iv
e 
in
du
ct
io
n 
of
 C
D
44
 p
ro
m
ot
er
0
10
20
30
40
- 1 -
2 1 1
- - 1
R
el
at
iv
e 
in
du
ct
io
n 
of
 C
D
44
 p
ro
m
ot
er
KLF1 WT KLF1 E325K
Flag-KLF1
Merge
DNA
Arnaud et al., Figure 3
Arnaud et al. 
 
 1
The American Journal of Human Genetics 
 
Supplemental Data 
 
A dominant mutation in the gene encoding the erythroid transcription 
factor KLF1 causes a congenital dyserythropoietic anemia 
 
Lionel Arnaud, Carole Saison, Virginie Helias, Nicole Lucien, Dominique Steschenko, Marie-
Catherine Giarratana, Claude Prehu, Bernard Foliguet, Lory Montout, Alexandre G. de Brevern, 
Alain Francina, Pierre Ripoche, Odile Fenneteau, Lydie Da Costa, Thierry Peyrard, Gail 
Coghlan, Niels Illum, Henrik Birgens, Hannah Tamary, Achille Iolascon, Jean Delaunay, Gil 
Tchernia and Jean-Pierre Cartron. 
 
 
Nine Figures and Two Tables 
 
Arnaud et al. 
 
 2
Figure S1. (A) Bone marrow smear from the CDA patient ME before splenectomy (sample taken on 
1997/07/14) showing marked erythroid hyperplasia (77%) with a majority of acidophilic erythroblasts 
(58%). Binucleated erythroblasts (1.0%), multinucleated erythroblasts (1.5%) and few karyorrhexis (star) 
are observed. In some erythroblasts, the cytoplasm contains fine or coarse basophilic stippling of pale 
grayish-blue (arrow). 
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Figure S1. (B) Bone marrow smear from the CDA patient ME after splenectomy (sample taken on 
2001/02/07) showing marked erythroid hyperplasia (80%) with a majority of acidophilic erythroblasts 
(55%). Binucleated erythroblasts (4.5%), multinucleated erythroblasts (2.5%) and few karyorrhexis (star) 
are observed. 
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Figure S2. (A) Transmission electron microscopy of circulating erythroblasts of the CDA patient 
ME showing tubulosaccular inclusions (stars) and elongated cylindrical structures (black arrows) in the 
cytoplasm, and abnormally large nuclear pores (white arrows). Original magnification ×10,000. 
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Figure S2. (B) Transmission electron microscopy of circulating erythroblasts of the CDA patient 
ME showing a wide area of endoreplication of the nuclear membrane. Original magnification ×8,000 (top 
panel) and ×35,000 (bottom panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arnaud et al. 
 
 6
Figure S2. (C) Scanning electron microscopy of blood of the CDA patient ME showing severe 
anisopoikilocytosis (top panel, original magnification ×1,930) and small invaginations in erythrocyte 
membrane (stars, bottom panel, original magnification ×4,590). The scale bars represent 10 µm. 
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Figure S3. (A) Flow cytometry analysis of cell markers CD44, CD47, GYPA, BCAM/Lu, ICAM4/LW, 
CD29 and DARC on erythrocytes of the CDA patient ME (right histograms, sample taken on 
2010/01/05) or his healthy mother (left histograms, sample taken at the same time). Erythrocytes were 
stained with mouse monoclonal antibodies (profiles in color) or an isotype control antibody (profile in 
black) and phycoerythrin-conjugated goat F(ab’)2 anti-mouse IgG(H+L), and were gated on FSC and SSC 
(density dot plots). This blood sample from patient ME was taken 4 years after his most recent transfusion, 
and thus was free of exogenous erythrocytes. Patient ME’s erythrocytes abnormally showed no 
expression of CD44, reduced expression of BCAM and ICAM4, and slightly increased expression of 
CD29. Similar results have consistently been observed on samples taken since 2003. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arnaud et al. 
 
 8
Figure S3. (B) Flow cytometry analysis of cell markers CD55, CD58, CD59, CD99, CD151, KEL and 
AChE on erythrocytes of the CDA patient ME (right histograms, sample taken on 2010/01/05) or his 
healthy mother (left histograms, sample taken at the same time). Erythrocytes were stained with mouse 
monoclonal antibodies (profiles in color) or an isotype control antibody (profile in black) and phycoerythrin-
conjugated goat F(ab’)2 anti-mouse IgG(H+L), and were gated on FSC and SSC (density dot plots). This 
blood sample from patient ME was taken 4 years after his most recent transfusion, and thus was free of 
exogenous erythrocytes. The expression of CD99 is highly variable and patient ME’s profile is not 
abnormal. 
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Figure S4. Flow cytometry analysis of CD44 expression in the nucleated cells present in the CDA 
patient ME’s peripheral blood, showing absence of CD44 on his erythroblasts but presence on his 
leukocyte populations. Nucleated blood cells were isolated by hypotonic erythrocyte lysis and triple 
stained with anti-CD44-APC or isotype antibody-APC, anti-CD71-PE and anti-CD45-FITC; granulocytes 
(panel 1) and monocytes (panel 2) were directly gated on FSC and SSC (top left contour plot), while 
lymphocytes (CD71-/CD45+, panel 3) and erythroblasts (CD71+/CD45-, panel 4) were further gated on 
CD71 and CD45 expression (bottom left contour plot); the labeling corresponding to anti-CD44-APC 
(colored histograms) or isotype antibody-APC (grey histograms) was analyzed with the same voltage for 
all cell populations. 
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Figure S5. Analysis of the water permeability of the CDA patient ME’s erythrocytes confirming his 
AQP1 deficiency. 
(A) Stopped-flow light scattering measurements of erythrocytes from a control donor (top left panel), an 
AQP1-/- person (also known as Conull blood group phenotype, top right panel), the CDA patient ME (bottom 
right panel) and his healthy mother (bottom left panel) in response to a 150 mOsm inwardly directed 
gradient of mannitol at 15°C; the rapid increase in light scattering results from the shrinkage of 
erythrocytes due to water efflux, allowing to determine their osmotic water permeability. 
(B) Osmotic water permeability coefficients (Pf) of indicated erythrocytes. As the extremely rare AQP1-/- 
individuals, patient ME’s erythrocytes showed severely reduced water permeability. Of note, AQP1 is a 
major erythrocyte membrane protein that carries the Colton blood group antigens as well as ABO blood 
group antigens. 
Due to AQP1 deficiency of patient ME’s erythrocytes, their Colton phenotype is expected to be Co(a-b-) 
while blood group genotyping (BioArraySolutions HEA BeadChip Kit) predicts the following extended 
phenotype: C+E–c+e+, K–k+, Kp(a–b+), Js(a–b+), Fy(a+b+), Jk(a+b–), M+N–S–s+, Lu(a–b+), Di(a–b+), 
Co(a+b–), Do(a–b+), Hy+Jo(a+), LW(a+b–), Sc:1,–2. 
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Figure S6. (A) Experimental sequence data of KLF1 from the CDA patient ME compared with 
genomic NCBI Reference Sequence NC_000019.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NNN coding sequence 
NNN untranslated sequence 
NNN intronic sequence 
 
GCCGCCTTGCCTTGCTTTGCCTTATCAGAGGCTGCAGCCAATCAGCTAAGGACAGAGAGGAGCCCTCGAAGGGGCTATCACAG
CCTCAGAGTTCACGAGGCAGCCGAGGAAGAGGAGGCTTGAGGCCCAGGGTGGGCACCAGCCAGCCATGGCCACAGCCGAGACC
GCCTTGCCCTCCATCAGCACACTGACCGCCCTGGGCCCCTTCCCGGACACACAGGATGACTTCCTCAAGGTGGGGCCTAGAAG
GTGGGGTCTAGGTGGGCTGGCTGGAATCCAGGGCCACAGTCACAGATCTTGGGGTCCAGACCTGCATCTTGACCTGAAATCAA
GAGACTTAACCAGGACTGAGGTACGCTCAGTCCAGGAGAGGAGATCTCAGCTTAGTCTGGCAGGGGGTGAGGAGGGTGGTCTA
GGGGTTTGAGGTTCTAAGTGTGATCTATTTCGGTAATAGAAAACGAAGGTAGCCTGGGCAACATGGTGAAACCCTATCTCTAC
AAAAAATACCAAAAACATTAGGCCAGGCATGGGGGCGTGTGCCTGTAGTCCCAGGTACTCCGTAGGCTGATGCAGGAGGATCA
TTAGAGCCCAGGAGATTAAGGATACAGTGAGCTGCACCACTGCACTCCAGCCTGGGCAAAAGAGTAAGACCCTATCTCAAGAA
AAAAAAAAAAAAAAAGGAACGAGATCTAGGCTCACAGACAATCTTCCAGATATCAGCGGGAAATGATGAGTGTGTCTGGGGGA
CATCCAAAATTTCGGAATTAATCTTGTTTTGGGAGACAGGGAAGGAGAGGGATGTTCTGGGGGAAAACTAAGTCAAGGCTGGC
ATCCTCTCCCCCGTCCCCTGCCAGTTTTCCATCTCCAGCAGCTCTGCTACCCCTTCCCCCATCCCCGAGTGTGGTTCCAGATA
GTGGAAGTCTTATCTCCTGTCTCCAGCCAGACCTGATCGGTTTCTGTCCCTGGAGCTGGGGGGGGAGCGGGGAGAGGGGCGGT
TAGAGGGGCAGTGTTGGGGAAGTGGGACAGACAGACAGGCAAACAAGACCCCTTTCCAAAGCCTCTGCGTCAGAGTGTCCAGC
CCGCGATGTCCCTGGGCAGGGCACCCCAGTGTCCACCGAACCTCGAGCTGCCTGCTCCCTCCCGCAGTGGTGGCGCTCCGAAG
AGGCGCAGGACATGGGCCCGGGTCCTCCTGACCCCACGGAGCCGCCCCTCCACGTGAAGTCTGAGGACCAGCCCGGGGAGGAA
GAGGACGATGAGAGGGGCGCGGACGCCACCTGGGACCTGGATCTCCTCCTCACCAACTTCTCGGGCCCGGAGCCCGGTGGCGC
GCCCCAGACCTGCGCTCTGGCGCCCAGCGAGGCCYCCGGGGCGCAATATCCGCCGCCGCCCGAGACTCTGGGCGCATATGCTG
GCGGCCCGGGGCTGGTGGCTGGGCTTTTGGGTTCGGAGGATCACTCGGGTTGGGTGCGCCCTGCCCTGCGAGCCCGGGCTCCC
GACGCCTTCGTGGGCCCAGCCCTGGCTCCAGCCCCGGCCCCCGAGCCCAAGGCGCTGGCGCTGCAACCGGTGTACCCGGGGCC
CGGCGCCGGCTCCTCGGGTGGCTACTTCCCGCGGACCGGGCTTTCAGTGCCTGCGGCGTCGGGCGCCCCCTACGGGCTACTGT
CCGGGTACCCCGCGATGTACCCGGCGCCTCAGTACCAAGGGCACTTCCAGCTCTTCCGCGGGCTCCAGGGACCCGCGCCCGGT
CCCGCCACGTCCCCCTCCTTCCTGAGTTGTTTGGGACCCGGGACGGTGGGCACTGGACTCGGGGGGACTGCAGAGGATCCAGG
TGTGATAGCCGAGACCGCGCCATCCAAGCGAGGCCGACGTTCGTGGGCGCGCAAGAGGCAGGCAGCGCACACGTGCGCGCACC
CGGGTTGCGGCAAGAGCTACACCAAGAGCTCCCACCTGAAGGCGCATCTGCGCACGCACACAGGTGAGGGGGCGGGGCCCCGG
ACATGAGAAAGGGCGCGGCGCCCGCTGTAGTTACAGGGGAAGAAGGGTTGCAGAGGGCGGGACTTGGACTTGGCTGGCCTCTG
AGAGTGAGTGCCTCCTTAAATTTTGTGCCCTAGGGGCCTCACTTTGTTCATCCTAGTCCCAGCCCAGGCTGAGTAAAGGGGTG
TGGCCAGATGCAGGGGACCCGGGGACATGACTGGGCAGACAGTGGCGCTTATGGCTTCCTTGTCCCCTAGGGGAGAAGCCATA
CGCCTGCACGTGGGAAGGCTGCGGCTGGAGATTCGCGCGCTCGGACRAGCTGACCCGCCACTACCGGAAACACACGGGGCAGC
GCCCCTTCCGCTGCCAGCTCTGCCCACGTGCTTTTTCGCGCTCTGACCACCTGGCCTTGCACATGAAGCGCCACCTTTGAGCC
CTGCCCTGGCACTTGGACTCTCCTAGTGACTGGGGATGGGACAAGAAGCCTGTTTGGTGGTCTCTTCACACGGACGCGCGTGA
CACAATGCTGGGTGGTTTTCCCACGAATGGACCCTCTCCTGGACTCGCGTTCCCAAAGATCCACCCAAATATCAAACACGGAC
CCATAGACAGCCCTGGGGGAGCCTCTTACGGAAAATCCGACAAGCCTTCAGCCACAGGGAGCCACACAGAGATGTCCAAACTG
TCGTGCAAACCCAGTGAGACAGACCGCCAAATAAACGGACTCAGTGGACACTCAGACCAGCTCCCAGATGGCCCTGGACAGCA
GGAGAGGGTGTGGGATGAGGCTTCCCAGAGACCCTGGGTCTAGAAAGCGGCTCCTGAAGGTCCCTTATTGTGGCTGATATTAA
CTGTCAATGGTTATGGGTCCTATAAAAATGCCCCTCCCAGATAAAGCTTCAGCGTTGGCCTGAATTTTGGGTTTTGGAGGCTG
GAAGATGGCAGGAGGCTGTAAACCTAGAGGTCATATTAGAGGG 
 
Y (heterozygous T/C) for NM_006563.3:c.304T>C, NP_006554.1:p.Ser102Pro (rs2072597) 
R (heterozygous G/A) for NM_006563.3:c.973G>A, NP_006554.1:p.Glu325Lys
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Figure S6. (B) Analysis of heterozygous KLF1 mutation c.973G>A (E325K) from the CDA patient 
ME in both directions with Mutation Surveyor software (SoftGenetics). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KLF1
19p13
ex1 ex2 ex3
c.973G>A
Arnaud et al. 
 
 13
Figure S7. Analysis of the erythrocyte membrane proteins from the CDA patient ME (CDA, sample 
taken on 2010/01/05) or a control (CTL) showing abnormal migration of Band 3 (arrows) as usually 
observed in CDA II but also slight reduction of spectrins (stars). Proteins were resolved either by 
Laemmli’s (left gel) or Fairbanks’ (right gel) electrophoretic method, and stained with Coomassie Blue. 
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Figure S8. Reverse phase liquid chromatography (RPLC) elution pattern of the hemolysate from 
the CDA patient ME showing the presence of the hydrophobic ζ-globin chain (retention time 84 min). This 
confirmed that the fast migrating hemoglobin observed in isoelectric focusing (IEF) was indeed embryonic 
hemoglobin Portland (ζ2γ2 tetramer). The peaks and the corresponding retention times of heme, β-, Gγ-, Aγ- 
and α-globin chains are indicated. 
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Figure S9. Flow cytometry analysis of cell markers CD44, CD47, GYPA, BCAM/Lu, ICAM4/LW, CD29 
and DARC on erythrocytes of the CDA patient SF (right histograms, sample taken on 2009/06/29) or a 
healthy control (left histograms). Erythrocytes were stained with mouse monoclonal antibodies (profiles in 
color) or an isotype control antibody (profile in black) and phycoerythrin-conjugated goat F(ab’)2 anti-
mouse IgG(H+L), and were gated on FSC and SSC (density dot plots). Patient SF’s erythrocytes 
abnormally showed no expression of CD44 and reduced expression of ICAM4; the small CD44+ 
population (9.5%, star) likely corresponded to the residual erythrocytes of the most recent transfusion 
(2009/04/20) and should be taken into account for the analysis of the other markers, especially ICAM4. 
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Table S1. Essential hematologic parameters of CDA patient ME from birth, before and after 
splenectomy. 
Red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean cellular volume (MCV), mean 
cellular hemoglobin (MCH), mean cellular hemoglobin concentration (MCHC), red-blood-cell distribution 
width (RDW), platelet count (PLT), mean platelet volume (MPV), white blood cell count (WBC). 
Macrocytosis, severe thrombocytosis and extremely high erythroblastosis appeared after splenectomy. 
The three last RBC transfusions were on January 2004 (PT-Hb 7.2 g/dL), February 2005 (PT-Hb 7.2 g/dL) 
and October 2006 (PT-Hb 7.3 g/dL). 
 
 
Date 12/12/1996 14/02/1997 14/03/1997 05/05/1997 16/09/1997 29/01/1998 20/07/1998 20/05/1999 17/08/1999 29/03/2000 03/07/2000 20/04/2001 14/05/2002 25/10/2005 28/10/2008 10/02/2009 05/01/2010
Age 1 day 2 months 3 months 5 months 9 months 1 year 1 year 2 years 2 years 3 years 3 years 4 years 5 years 8 years 11 years 12 years 13 years
(Hospital) (Strasbourg) (Strasbourg) (Strasbourg) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Paris) (Paris) (Nancy) (Nancy) (Nancy) (Nancy)
Parameters Units
RBC 1012/L 4,0 2,7 3,8 3,3 2,2 2,7 2,7 2,4 2,7 1,7 1,9 2,5 2,5 2,3 2,7 2,9 2,6
HGB g/dL 11,5 7,5 11,4 9,4 6,5 7,4 7,6 6,7 7,6 4,7 5,4 8,0 8,4 7,5 8,4 9,1 8,0
HCT % 34,1 22,5 33,9 27,9 19,4 21,9 22,8 20,0 23,5 14,2 16,7 26,0 27,0 23,5 27,6 30,1 26,7
MCV fL 86,3 85,0 89,0 83,6 87,7 82,3 84,8 83,8 87,4 85,3 85,9 106,9 108,9 101,0 102,4 102,8 103,4
MCH pg 29,1 28,1 29,9 2,8 29,4 27,8 28,2 28,0 28,2 28,3 27,8 32,2 33,8 32,2 31,1 31,1 31,0
MCHC g/dL 33,7 33,0 33,6 33,7 33,5 33,8 33,3 33,5 32,3 33,1 32,3 30,1 31,0 31,9 30,4 30,2 30,0
RDW % 18,4 16,7 14,6 14,1 14,6 17,5 13,9 20,9 18,2 20,6 24,0
Reticulocytes 109/L 52,5 13,9 62,9 9,0 80,7 134,0 21,5 838 362 422 351 469 304
PLT 109/L 406,0 393,0 229,0 380,0 447,0 339,0 223,0 230,0 211,0 173,0 83,0 526,0 612,0 1020,0 1101,0 1036,0 1264,0
MPV fL 10,4 12,0 10,3 8,9 7,9 8,4 8,6 8,1 8,5 7,8 7,3 10,6 9,3 7,5 9,2 8,1 8,3
WBC 109/L 9,8 20,4 8,2 8,1 13,0 24,2 11,9 15,9 16,0 19,2 27,8 22,7 24,9 15,9 13,9 16,3 16,4
Neutrophils 109/L 3,2 13,5 2,1 1,5 3,7 5,6 3,3 5,6 3,5 11,9 18,6 7,1 7,7 7,8 5,5 9,8 9,2
Eosinophils 109/L 0,4 0,6 0,2 0,3 0,2 0,2 0,1 0,3 0,1 0,2 0,2 1,4 0,8 0,3 0,3 0,3 0,2
Basophils 109/L 0,0 0,0 0,0 0,1 0,2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1 0,2 0,0
Lymphocytes 109/L 3,6 3,3 4,8 4,8 7,4 16,5 6,3 8,4 9,8 6,3 7,2 10,9 14,7 6,4 6,1 4,7 4,8
Monocytes 109/L 1,1 2,0 1,2 1,2 1,0 1,9 2,1 1,6 2,6 0,8 1,7 3,4 1,5 1,1 1,8 1,3 1,8
Neutrophils % 33,0 66,0 25,0 18,5 28,4 23,0 28,0 35,0 22,0 62,0 67,0 31,0 34,0 34,3 24,4 42,9 40,5
Eosinophils % 4,0 3,0 2,0 3,8 1,7 1,0 1,0 2,0 0,4 0,8 0,6 6,0 3,3 1,4 1,2 1,5 0,7
Basophils % 0,0 0,0 0,0 0,7 1,4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,6 0,7 0,0
Lymphocytes % 37,0 16,0 58,0 59,1 56,9 68,0 53,0 53,0 61,0 33,0 26,0 48,0 64,7 28,0 26,8 20,7 20,9
Monocytes % 11,0 10,0 14,0 14,4 7,7 8,0 18,0 10,0 16,0 4,0 6,0 15,0 6,6 4,8 7,9 5,7 8,0
Erythroblasts /100 WBCs 470 12 128 few 12 30 few 100 110 80 210 920 594 1000 1000 500 500
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Table S2. PCR and sequencing primers used to sequence KLF1. 
Location and direction of the primers are based on NCBI KLF1 mRNA Reference Sequence 
NM_006563.3 while position is based on NCBI human chromosome 19 genomic contig NT_011295.11. 
Complete KLF1 was sequenced after PCR amplification of two overlapping fragments using high fidelity 
DNA polymerase as follows. A 5’ KLF1 fragment was amplified by semi-nested PCR with primers KLF1-1, 
KLF1-2 and KLF1-11, and sequenced with primers KLF1-2, KLF1-6 and KLF1-15. A 3’ KLF1 fragment 
was amplified by semi-nested PCR with primers KLF1-7, KLF1-3 and KLF1-4, and sequenced with 
primers KLF1-7, KLF1-8 and KLF1-4. PCR products were sequenced with ABI BigDye terminator 
chemistry (GATC Biotech) after gel purification (Macherey-Nagel). Sequencing data were analyzed with 
DNA Workbench software (CLC bio) and Mutation Surveyor software (SoftGenetics). 
 
 
Name Sequence Location Direction Position
KLF1-1 TAGTCTTTAACCCCAGCCCCAG 5' side of exon 1 Sense 4260969-4260948
KLF1-2 ACGTGAAGTTTGTGCCCCAG 5' side of exon 1 Sense  4260939-4260920
KLF1-3 AGGGGGCTTGTTGGAGTTGAG 3' side of exon 3 Antisense 4257897-4257917
KLF1-4 AGGAGATGAGGGTGTGTAAGG 3' side of exon 3 Antisense  4257935-4257955
KLF1-6 TGATCGGTTTCTGTCCCTGG Intron 1 Sense  4259958-4259939
KLF1-7 AGGATCACTCGGGTTGGGT Exon 2 Sense  4259457-4259439
KLF1-8 TACACCAAGAGCTCCCACC Exon 2 Sense 4258978-4258960
KLF1-11 CGGGTCCCAAACAACTCAG Exon 2 Antisense  4259122-4259140
KLF1-15 GCTTTGGAAAGGGGTCTTG Intron 1 Antisense  4259847-4259865  
 
 
